Ecto-NTPDase-Inhibitors
Inhibitors for use in human therapy Invention
The invention provides a new class of nucleosides exhibiting a high affinity for individual ecto-nucleotidetriphosphate-diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors).
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Single-Celled Heroes: Foraminifera’s Power to Combat Ocean Phosphate Pollution
So-called foraminifera are found in all the world’s oceans. Now an international study led by the University of Hamburg has shown that the microorganisms, most of which bear shells, absorb…
Humans vs Machines—Who’s Better at Recognizing Speech?
Are humans or machines better at recognizing speech? A new study shows that in noisy conditions, current automatic speech recognition (ASR) systems achieve remarkable accuracy and sometimes even surpass human…
Not Lost in Translation: AI Increases Sign Language Recognition Accuracy
Additional data can help differentiate subtle gestures, hand positions, facial expressions The Complexity of Sign Languages Sign languages have been developed by nations around the world to fit the local…